Literature DB >> 23322678

Rapid diagnostic HCV antibody assays.

Bryce D Smith1, Amy Jewett, Jan Drobeniuc, Saleem Kamili.   

Abstract

Approximately 4.1 million Americans have been infected with HCV and 45-85% of chronically infected persons are unaware of their status. Rapid anti-HCV assays can assist and expedite the identification of those unaware of their infection. Performance characteristics of pre-market rapid anti-HCV assays (Chembio, MedMira and OraSure) have been evaluated. Their sensitivity (78.9-99.3%) and specificity (80-100%) varied. Future investigations could include evaluation of rapid anti-HCV tests in persons who are coinfected with HCV and HIV, and development of rapid HCV-antigen tests and nucleic acid tests.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23322678      PMCID： PMC5791540          DOI： 10.3851/IMP2470

Source DB:  PubMed          Journal:  Antivir Ther        ISSN： 1359-6535


  35 in total

1.  Predictors of failure to return for HIV test result and counseling by test site type.

Authors:  F Molitor; R A Bell; S R Truax; J D Ruiz; R K Sun
Journal:  AIDS Educ Prev       Date:  1999-02

2.  Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid.

Authors:  Stephen R Lee; Keith W Kardos; Eugene Schiff; Cheryl A Berne; Karam Mounzer; Alpha T Banks; Harvey A Tatum; Timothy J Friel; Michael P Demicco; William M Lee; Scott E Eder; Alexander Monto; Graham D Yearwood; Geraldine B Guillon; Lisa A Kurtz; Mark Fischl; Jay Lynn Unangst; Laura Kriebel; Gary Feiss; Michele Roehler
Journal:  J Virol Methods       Date:  2010-12-21       Impact factor: 2.014

3.  Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco.

Authors:  J A Hahn; K Page-Shafer; P J Lum; K Ochoa; A R Moss
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

4.  HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression.

Authors:  Bahareh Vali; R Brad Jones; Ali Sakhdari; Prameet M Sheth; Kiera Clayton; Feng-Yun Yue; Gabor Gyenes; David Wong; Marina B Klein; Sahar Saeed; Erika Benko; Colin Kovacs; Rupert Kaul; Mario A Ostrowski
Journal:  Eur J Immunol       Date:  2010-09       Impact factor: 5.532

5.  Delivering care to injection drug users coinfected with HIV and hepatitis C virus.

Authors:  Lynn E Taylor
Journal:  Clin Infect Dis       Date:  2005-04-15       Impact factor: 9.079

6.  Rapid hiv testing in urban outreach: a strategy for improving posttest counseling rates.

Authors:  P A Keenan; J M Keenan
Journal:  AIDS Educ Prev       Date:  2001-12

7.  Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.

Authors:  G Greub; B Ledergerber; M Battegay; P Grob; L Perrin; H Furrer; P Burgisser; P Erb; K Boggian; J C Piffaretti; B Hirschel; P Janin; P Francioli; M Flepp; A Telenti
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

8.  Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus.

Authors:  Bryce D Smith; Jan Drobeniuc; Amy Jewett; Bernard M Branson; Richard S Garfein; Eyasu Teshale; Saleem Kamili; Cindy M Weinbaum
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

9.  Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996-2007.

Authors:  Philip R Spradling; James T Richardson; Kate Buchacz; Anne C Moorman; Lyn Finelli; Beth P Bell; John T Brooks
Journal:  J Acquir Immune Defic Syndr       Date:  2010-03       Impact factor: 3.731

10.  Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.

Authors:  Joseph J Amon; Richard S Garfein; Linda Ahdieh-Grant; Gregory L Armstrong; Lawrence J Ouellet; Mary H Latka; David Vlahov; Steffanie A Strathdee; Sharon M Hudson; Peter Kerndt; Don Des Jarlais; Ian T Williams
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079
View more
  7 in total

Review 1.  Pharmacy-Based Infectious Disease Management Programs Incorporating CLIA-Waived Point-of-Care Tests.

Authors:  S R Herbin; D G Klepser; M E Klepser
Journal:  J Clin Microbiol       Date:  2020-04-23       Impact factor: 5.948

2.  A pilot study of rapid hepatitis C virus testing in the Rhode Island Department of Corrections.

Authors:  Curt G Beckwith; Ann E Kurth; Lauri B Bazerman; Emily J Patry; Alice Cates; Liem Tran; Amanda Noska; Irene Kuo
Journal:  J Public Health (Oxf)       Date:  2015-03-02       Impact factor: 2.341

3.  Diagnostic accuracy of point-of-care tests for hepatitis C virus infection: a systematic review and meta-analysis.

Authors:  Mehnaaz Sultan Khuroo; Naira Sultan Khuroo; Mohammad Sultan Khuroo
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

4.  Development of a Rapid Automated Fluorescent Lateral Flow Immunoassay to Detect Hepatitis B Surface Antigen (HBsAg), Antibody to HBsAg, and Antibody to Hepatitis C.

Authors:  Ji Hyeong Ryu; Minsuk Kwon; Joung Dae Moon; Min Woong Hwang; Jeong Min Lee; Ki Hyun Park; So Jeong Yun; Hyun Jin Bae; Aeran Choi; Hyeyoung Lee; Bongsu Jung; Juhee Jeong; Kyungja Han; Yonggoo Kim; Eun Jee Oh
Journal:  Ann Lab Med       Date:  2018-11       Impact factor: 3.464

5.  Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort.

Authors:  Emily Adland; Gerald Jesuthasan; Louise Downs; Victoria Wharton; Gemma Wilde; Anna L McNaughton; Jane Collier; Eleanor Barnes; Paul Klenerman; Monique Andersson; Katie Jeffery; Philippa C Matthews
Journal:  BMC Infect Dis       Date:  2018-09-14       Impact factor: 3.090

Review 6.  Developments in the HCV Screening Technologies Based on the Detection of Antigens and Antibodies.

Authors:  Shrikant Dashrath Warkad; Keum-Soo Song; Dilipkumar Pal; Satish Balasaheb Nimse
Journal:  Sensors (Basel)       Date:  2019-09-30       Impact factor: 3.576

7.  Hepatitis C outreach project and cross-sectional epidemiology in high-risk populations in Trondheim, Norway.

Authors:  Raisa Hannula; Jonas Söderholm; Therese Svendsen; Maja Skaland; Svein A Nordbø; Harald Steinum; Jan K Damås
Journal:  Ther Adv Infect Dis       Date:  2021-10-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.